Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2008

TPG Biotech to Fund Development of Two Drugs from JCR

  • TPG Biotech will fund the late-stage clinical development of two drug candidates from JCR Pharmaceuticals: JR-013 and Growject®. Under the terms of the agreement, TPG Biotech will fund the development of the drugs and in return will receive milestone payments, royalties, and warrants to purchase JCR’s common stock.

    JR-013 is a recombinant human erythropoietin for the treatment of renal anemia in dialysis patients. The drug was originated by JCR and is currently undergoing Phase II/III studies in Japan.

    Growject is currently approved and marketed in Japan to treat short stature in children with growth hormone deficiency and Turner’s syndrome. JCR is extending Growject use to treat adult growth hormone deficiency (AGHD). Clinical studies for AGHD have been completed and application for an approval of this extended use has been filed with the Japanese Ministry of Health, Labor and Welfare.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »